Adial Pharmaceuticals Inc (ADIL)
$1
Performance
- $0.98$1.04$1.00
2.0%
Downside
Day's Volatility :5.77%
Upside
3.85%
- $0.77$4.30$1.00
23.5%
Downside
52 Weeks Volatility :82.21%
Upside
76.74%
Returns
| Period | Adial Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -19.22% | 0.0% |
6 Months | -52.83% | 0.0% |
1 Year | -71.18% | 0.0% |
3 Years | -99.12% | -22.3% |
Highlights
Market Capitalization | 6.7M |
Book Value | $1.0 |
Earnings Per Share (EPS) | -3.99 |
Wall Street Target Price | 7.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -104.18% |
Return On Equity TTM | -320.96% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -7.3M |
Diluted Eps TTM | -3.99 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.89 |
EPS Estimate Next Year | -1.16 |
EPS Estimate Current Quarter | -0.53 |
EPS Estimate Next Quarter | -0.37 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 650.0%
Technicals Summary
Sell
Neutral
Buy
Adial Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Adial Pharmaceuticals Inc | 0.9% | -52.83% | -71.18% | -99.12% | -97.39% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Adial Pharmaceuticals Inc | 0.02 | NA | NA | -2.89 | -3.21 | -1.04 | NA | 1.0 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Adial Pharmaceuticals Inc | Buy | $6.7M | -97.39% | 0.02 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Adial Pharmaceuticals Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 108.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 168.3%
Institutional Holdings
Renaissance Technologies Corp
0.80%Manchester Capital Management LLC
0.75%HRT FINANCIAL LLC
0.56%BlackRock Inc
0.43%Virtu Financial LLC
0.32%UBS Group AG
0.09%
Company Information
adial pharmaceuticals is dedicated to personalized treatment for drug abuse and addiction. while our pipeline includes drug candidates for the treatment of opiate and amphetamine use, our two lead drug candidates are for the treatment of alcohol abuse. adial leverages its extensive knowledge of pharmacology and pharmacogenomics to change the paradigm of drug abuse treatment.
Organization | Adial Pharmaceuticals Inc |
Employees | 4 |
CEO | Mr. Cary John Claiborne MBA |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$1.00
-1.96%
Keyarch Acquisition Corp
$1.00
-1.96%
Connexa Sports Technologies Inc
$1.00
-1.96%
Us Value Etf
$1.00
-1.96%
First Wave Biopharma Inc
$1.00
-1.96%
Global X Msci Next Emerging
$1.00
-1.96%
Fat Projects Acquisition Corp
$1.00
-1.96%
Capital Link Global Fintech
$1.00
-1.96%
Applied Uv Inc
$1.00
-1.96%